JB Pharma is consistently building on its investor confidence. As per the IQVIA Market Reflection Report for the month of August 2022, JB Pharma is sitting pretty, ranked at a healthy 23 among the Indian Pharmaceutical players and underlining its meteoric rise with an outstanding growth rate of 20% for the month, the highest among all other companies in the top 30 Indian Pharmaceutical companies list.

While the rest of the players in the Report show single and conservative double-digit growth, JB Pharma has raced away from the competition, proving yet again that it would be just a matter of time before they would be counted among the top 20 Indian Pharma big guns. The Report specifically states that on both counts of TSA (Total Sales Audit) and SSA (Secondary Sales Audit) numbers, JB Pharma performed admirably well posting the highest growth for the month of August 2022 and also posted the highest growth for MAT (Moving Annual Total) for the 12-month period ending with August 2022.

Nikhil Chopra, CEO and Whole Time Director exuded confidence by saying, “Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business. This is in continuation of our First Quarter results of FY23, with a growth rate of over 25%, outperforming the market rate of 18% (IQVIA, MAT Jun’22). We are confident that by the end of this quarter, we shall continue to log 20% plus growth rate conforming to all our market projections for the year.”

JB Pharma has recently unveiled their new identity, which is a reflection of the way the company thinks and operates, symbolizing the belief in continuing to be GOOD PEOPLE for GOOD HEALTH. With this defined growth agenda, solid values and dedication towards creating sustainable advantages through key products, JB Pharma is approaching the new financial year with new vigor and purpose.